Drugs / LEP-F1
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06627257 | Jan 2025 → Mar 2026 overdue | leprosy | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT03302897 | Oct 2017 → Mar 2019 | leprosy | Access to Advanced Health Institute (AAHI) | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03947437 | Feb → Mar 2024 | leprosy | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LEP-F1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06627257 ↗ |
| Modality | Protein / enzyme biologic | “recombinant four-antigen Mycobacterium leprae antigen LEP-F1” NCT03302897 ↗ |
| Route | Intramuscular | “2 μg LEP-F1 + 5 μg GLA-SE will be administered by IM injection on Days 0, 28, and 56 in healthy participants.” NCT03947437 ↗ |